Physician profile
John M Stern
NPI 1164440442
$998,678.36
in general payments reported to CMS, 2019-2025
15 companies · $197K in 2025
The $197K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $71K · 2021: $86K · 2022: $169K · 2023: $165K · 2024: $212K · 2025: $197K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $260K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Honoraria: $82K · Travel and Lodging: $53K · Food and Beverage: $11K · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $260,024.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,041.00 |
| Honoraria | $81,650.00 |
| Travel and Lodging | $53,205.98 |
| Food and Beverage | $11,274.06 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $253,446.72 | 2019-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Sk Life Science, INC. | $153,827.18 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $148,775.18 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb, INC. | $120,682.30 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Neurelis, INC. | $116,638.42 | 2020-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $74,898.51 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $34,963.71 | 2019-2022 | |
| Greenwich Biosciences, INC. | $34,590.65 | 2019-2021 | |
| Ucb Sa | $25,671.14 | 2019-2025 | |
| Eisai INC. | $20,976.68 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $6,622.05 | 2023 | Aptiom |
| Eisai Co., Ltd. | $5,680.00 | 2019 | |
| Zogenix INC. | $1,550.00 | 2021 | |
| Aquestive Therapeutics, INC. | $255.00 | 2021 | |
| Neuropace, INC. | $100.82 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$349,464.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.